JP2019512002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512002A5 JP2019512002A5 JP2018539317A JP2018539317A JP2019512002A5 JP 2019512002 A5 JP2019512002 A5 JP 2019512002A5 JP 2018539317 A JP2018539317 A JP 2018539317A JP 2018539317 A JP2018539317 A JP 2018539317A JP 2019512002 A5 JP2019512002 A5 JP 2019512002A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- seq
- acid sequence
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021153453A JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291143P | 2016-02-04 | 2016-02-04 | |
| US62/291,143 | 2016-02-04 | ||
| PCT/US2017/016407 WO2017136659A2 (en) | 2016-02-04 | 2017-02-03 | Humanized anti-cd3 antibodies, conjugates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153453A Division JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512002A JP2019512002A (ja) | 2019-05-09 |
| JP2019512002A5 true JP2019512002A5 (enExample) | 2020-03-26 |
| JP6951826B2 JP6951826B2 (ja) | 2021-10-20 |
Family
ID=59501004
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539317A Active JP6951826B2 (ja) | 2016-02-04 | 2017-02-03 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
| JP2021153453A Pending JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153453A Pending JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12252534B2 (enExample) |
| EP (1) | EP3411069B1 (enExample) |
| JP (2) | JP6951826B2 (enExample) |
| KR (1) | KR102891788B1 (enExample) |
| CN (1) | CN109069635B (enExample) |
| AU (1) | AU2017213886B2 (enExample) |
| CA (1) | CA3013463C (enExample) |
| ES (1) | ES2992761T3 (enExample) |
| WO (1) | WO2017136659A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10351626B2 (en) | 2013-03-14 | 2019-07-16 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
| JP6951826B2 (ja) | 2016-02-04 | 2021-10-20 | ザ スクリプス リサーチ インスティテュート | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
| EP3668898B1 (en) | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| KR101973060B1 (ko) * | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| US12377294B2 (en) * | 2018-08-28 | 2025-08-05 | Ambrx, Inc. | Anti-CD3 antibody folate bioconjugates and their uses |
| US20220089722A1 (en) * | 2018-12-29 | 2022-03-24 | Nantong Yichen Biopharma. Co. Ltd. | Heterodimeric fusion protein |
| WO2020168555A1 (zh) * | 2019-02-22 | 2020-08-27 | 武汉友芝友生物制药有限公司 | Cd3抗原结合片段及其应用 |
| WO2020232165A1 (en) * | 2019-05-14 | 2020-11-19 | Qlb Biotherapeutics | Bispecific anti-cd3 x cd20 antibodies and uses thereof |
| TWI905099B (zh) | 2019-05-21 | 2025-11-21 | 瑞士商諾華公司 | Cd19 結合分子及其用途 |
| TWI841790B (zh) * | 2019-09-30 | 2024-05-11 | 大陸商和鉑醫藥（上海）有限責任公司 | 靶向cd3的抗體、雙特異性抗體及其用途 |
| CN113677704B (zh) * | 2019-11-22 | 2024-03-26 | 南通壹宸生物医药科技有限公司 | Psma抗体及其应用 |
| TWI827807B (zh) * | 2020-02-26 | 2024-01-01 | 香港商潤俊（中國）有限公司 | 抗cd3抗體葉酸生物共軛物及其用途 |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| MX2023002194A (es) | 2020-08-25 | 2023-03-03 | Gilead Sciences Inc | Moleculas multiespecificas de union a antigenos dirigidas al vih y metodos de uso. |
| CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
| EP4384218A4 (en) * | 2021-08-09 | 2025-11-05 | Merck Patent Gmbh | Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| WO2024108032A2 (en) * | 2022-11-18 | 2024-05-23 | Jn Biosciences Llc | Anti-cd3 antibodies |
| EP4622631A1 (en) | 2022-11-23 | 2025-10-01 | University of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for increasing immune responses |
| WO2024191168A1 (ko) * | 2023-03-13 | 2024-09-19 | 머스트바이오 주식회사 | 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| CN1589151A (zh) | 2001-09-21 | 2005-03-02 | 图兰恩教育基金管理人 | 诊断或治疗性促生长素抑制素或铃蟾肽类似物的连接物及其用途 |
| US7122622B2 (en) | 2002-04-16 | 2006-10-17 | Biosynthema Inc. | Peptide compounds having improved binding affinity to somatostatin receptors |
| CA2523716C (en) | 2003-05-31 | 2014-11-25 | Micromet Ag | Human anti-human cd3 binding molecules |
| KR101189533B1 (ko) | 2004-03-30 | 2012-10-11 | 가부시끼가이샤 구레하 | 비수전해질 이차 전지용 음극 재료, 그 제조 방법, 음극 및전지 |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| WO2007058725A2 (en) * | 2005-10-12 | 2007-05-24 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| US20090018029A1 (en) | 2005-11-16 | 2009-01-15 | Ambrx, Inc. | Methods and Compositions Comprising Non-Natural Amino Acids |
| ES2529065T3 (es) | 2005-12-14 | 2015-02-16 | Ambrx, Inc. | Composiciones que contienen, procedimientos que implican y usos de aminoácidos no naturales y polipéptidos |
| CA2632832A1 (en) | 2005-12-30 | 2007-07-12 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| JP2009523815A (ja) | 2006-01-19 | 2009-06-25 | アンブルックス，インコーポレイテッド | 免疫原性が調節された非天然アミノ酸ポリペプチド |
| JP2010512800A (ja) | 2006-12-18 | 2010-04-30 | アンブルックス，インコーポレイテッド | 非天然のアミノ酸およびポリペプチドを含んでいる組成物、これらが関連する方法、ならびにこれらの利用 |
| US20100098630A1 (en) | 2006-12-28 | 2010-04-22 | Ambrx, Inc. | Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides |
| PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
| EP2211903A4 (en) | 2007-10-17 | 2011-07-06 | Nuvelo Inc | CLL-1 ANTIBODY |
| EP2225275A4 (en) | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| HRP20151367T1 (hr) | 2008-05-13 | 2016-01-29 | Yale University | Kimerne male molekule za pojaäśanje odgovora protutijela na stanice raka |
| CA2738033C (en) | 2008-09-26 | 2019-11-26 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| CN107827985A (zh) * | 2011-05-21 | 2018-03-23 | 宏观基因有限公司 | 能够与人和非人cd3结合的cd3结合分子 |
| KR102179369B1 (ko) | 2011-05-27 | 2020-11-16 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| EP2714685B1 (en) | 2011-05-27 | 2016-10-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| HRP20181717T1 (hr) | 2012-09-27 | 2018-12-28 | Merus N.V. | Bispecifična igg protutijela kao aktivatori t stanice |
| BR112015007120A2 (pt) * | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| WO2014131711A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US10351626B2 (en) | 2013-03-14 | 2019-07-16 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
| TW201446804A (zh) | 2013-05-14 | 2014-12-16 | Ambrx公司 | 新穎多肽小分子結合物及其用途 |
| US9790224B2 (en) | 2013-06-07 | 2017-10-17 | Rhizen Pharmaceuticals Sa | Dual selective PI3 delta and gamma kinase inhibitors |
| EP3057991B8 (en) | 2013-10-15 | 2019-09-04 | The Scripps Research Institute | Chimeric antigen receptor t cell switches and uses thereof |
| EP3066133A1 (en) | 2013-11-04 | 2016-09-14 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| KR102225489B1 (ko) * | 2013-12-17 | 2021-03-10 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| TWI742423B (zh) | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| AU2015292406B2 (en) * | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
| EP3283113A4 (en) | 2015-04-15 | 2018-12-05 | The California Institute for Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
| JP6951826B2 (ja) | 2016-02-04 | 2021-10-20 | ザ スクリプス リサーチ インスティテュート | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
-
2017
- 2017-02-03 JP JP2018539317A patent/JP6951826B2/ja active Active
- 2017-02-03 US US16/074,600 patent/US12252534B2/en active Active
- 2017-02-03 AU AU2017213886A patent/AU2017213886B2/en active Active
- 2017-02-03 KR KR1020187025472A patent/KR102891788B1/ko active Active
- 2017-02-03 CN CN201780024266.1A patent/CN109069635B/zh active Active
- 2017-02-03 CA CA3013463A patent/CA3013463C/en active Active
- 2017-02-03 ES ES17748229T patent/ES2992761T3/es active Active
- 2017-02-03 WO PCT/US2017/016407 patent/WO2017136659A2/en not_active Ceased
- 2017-02-03 EP EP17748229.6A patent/EP3411069B1/en active Active
-
2021
- 2021-09-21 JP JP2021153453A patent/JP2022023052A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512002A5 (enExample) | ||
| AR111361A1 (es) | Anticuerpos biespecíficos de unión específica a pd1 y lag3 | |
| WO2015138907A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2013530929A5 (enExample) | ||
| CY1114851T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| RU2015147300A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
| FI3596125T3 (fi) | Anti-PAR2-vasta-aineita ja niiden käyttöjä | |
| CY1118008T1 (el) | Πρωτεϊνες δεσμευσης ετεροδιμερους και χρησεις αυτων | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| JP2017518083A (ja) | ｉｎ ｖｉｖｏでの非共有結合的連結のための方法および組成物 | |
| JP2005120106A5 (enExample) | ||
| CN102838663B (zh) | 定点突变和定点修饰的病毒膜蛋白、其制备方法及其应用 | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| Okochi et al. | Array-based rational design of short peptide probe-derived from an anti-TNT monoclonal antibody | |
| NZ598770A (en) | Monoclonal antibodies | |
| JP2013538791A5 (enExample) | ||
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| WO2019104155A3 (en) | Chemical probe-dependent evaluation of protein activity and uses thereof | |
| JP2016512251A5 (enExample) | ||
| JP2014506448A5 (enExample) |